Nanite, founded with a mission to revolutionize gene therapy, focuses on developing next-generation non-viral gene delivery systems. The company leverages its AI-driven platform, SAYER, to create programmable polymer nanoparticles designed for tissue-specific delivery across various medical modalities and indications. Nanite aims to provide safer and more efficient alternatives to viral vectors, addressing critical needs in gene therapy for diseases like cystic fibrosis and HIV.
Notable affiliations include collaborations with the Cystic Fibrosis Foundation and funding from the Bill & Melinda Gates Foundation. Key achievements include securing a $1.8 million award for HIV gene therapy research. Nanite's innovative approach has positioned it as a leader in the non-viral gene delivery space, promising significant advancements in the treatment of genetic disorders and enhancing the overall impact of gene therapy.
